TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions
Cancer
Interventions
DRUG

TTX-080

Variable dose (Q3W)

DRUG

TTX-080

Specified dose (Q3W)

DRUG

pembrolizumab

Specified dose (Q3W)

DRUG

cetuximab

Specified dose on specified days

DRUG

FOLFIRI

Specified dose (Q2W)

DRUG

cetuximab

Specified dose (Q2W)

DRUG

TTX-080

Specified dose (Q2W)

Trial Locations (39)

10029

COMPLETED

Icahn School of Medicine at Mount Sinai, New York

11794

COMPLETED

Stony Brook University, Stony Brook

15232

COMPLETED

University of Pittsburgh Medical Center, Pittsburgh

19713

COMPLETED

Christiana Care Helen F. Graham Cancer Center, Newark

20016

COMPLETED

John Hopkins Kimmer Cancer Center, Washington D.C.

20904

RECRUITING

Maryland Oncology Hematology, Silver Spring

22031

RECRUITING

NEXT Oncology Virginia, Fairfax

29425

COMPLETED

Medical University of South Carolina, Charleston

32003

COMPLETED

Florida Cancer Specialists, Fleming Island

32117

RECRUITING

Florida Cancer Specialists, Daytona Beach

32804

COMPLETED

AdventHealth Research Institute, Orlando

34474

RECRUITING

Ocala Oncology Center, Ocala

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

37232

COMPLETED

Vanderbilt - Ingram Cancer Center, Nashville

40241

COMPLETED

Norton Cancer Institute, Louisville

43219

COMPLETED

Zangmeister Cancer Center, Columbus

43606

COMPLETED

The University of Toledo, Toledo

45267

RECRUITING

University of Cincinnati, Cincinnati

46202

COMPLETED

Indiana University, Indianapolis

49546

COMPLETED

START Midwest, Grand Rapids

55101

RECRUITING

Regions Hospital Cancer Care Center, Saint Paul

60005

COMPLETED

Illinois Cancer Specialists, Arlington Heights

60612

COMPLETED

University of Illinois, Chicago

63110

COMPLETED

Washington University in St Louis, St Louis

68130

RECRUITING

Nebraska Cancer Center Oncology Hematology West P.C., Omaha

73104

RECRUITING

University of Oklahoma, Oklahoma City

75246

RECRUITING

Texas Oncology - Dallas, Dallas

75460

RECRUITING

Texas Oncology - Paris, Paris

77030

COMPLETED

The University of Texas MD Anderson Cancer Center, Houston

78229

COMPLETED

NEXT Oncology, San Antonio

80218

RECRUITING

Rocky Mountain Cancer Centers, Denver

85711

COMPLETED

Arizona Oncology Associates, Tucson

90033

COMPLETED

University of Southern California, Los Angeles

92663

COMPLETED

Hoag Memorial Hospital, Newport Beach

98405

COMPLETED

Northwest Medical Specialties, Tacoma

98684

COMPLETED

Northwest Cancer Specialists, Vancouver

06511

COMPLETED

Yale Cancer Center, New Haven

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

Tizona Therapeutics, Inc

INDUSTRY

NCT04485013 - TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | Biotech Hunter | Biotech Hunter